Ramadevi Pemmireddy1, Ravikiran Alvala2, Venkatesh Sama3, Aparna Sriramoju1
1Department of Pharmacology, G. Pullareddy College of Pharmacy, Hyderabad, Telangana, India
2Department of Biotechnology, G. Pullareddy College of Pharmacy, Hyderabad, Telangana, India
3Department of Pharmacognosy, G. Pullareddy College of Pharmacy, Hyderabad, Telangana, India
*Address for Corresponding Author
Assistant Professor, Department of Pharmacology, Sree Dattha Institute of Pharmacy, Hyderabad, Telangana, India
Objective: The purpose of the present study was to evaluate the effect of Ranolazine on DMH induced colon cancer in mice. Material and Methods: Group I (Normal control): Received vehicle p.o. for 7 weeks. Group II (Disease group): Received DMH (20mg/kg) s.c. twice a week for 2 weeks. Group III (Standard control): Received DMH (20mg/kg) s.c. twice a week for 2 weeks and 5-fluoro uracil (20 mg/kg) i.p. for 14 consecutive days. Group IV (Ranolazine 10): Received DMH (20mg/kg) s.c. twice a week for 2 weeks and Ranolazine (10 mg/kg) p.o. for twice a week for 7 weeks. Group V (Ranolazine 20): Received DMH (20mg/kg) s.c. twice a week for 2 weeks and Ranolazine (20 mg/kg) p.o. twice a week for 7 weeks. At the end of the treatment period, all the animals were sacrificed by cervical dislocation and the colons were isolated. Finally, the colonic tissues were used for quantification of aberrant crypt foci, biochemical estimations (MDA, GSH, Catalase and SOD) and histological examination. Results: Mice treated with DMH showed high incidents of aberrant crypt foci along with malondialdehyde (MDA) and decreased GSH, SOD and Catalase levels. Histopathalogical evaluation of colon in DMH treated mice also showed dysplasia, inflammation and focal congestion in sub-mucosa and muscularis layers. The treatment with Ranolazine reversed all the above effects and restored to the normal level. Conclusion: In conclusion, the present study suggests that treatment with Ranolazine significantly decreased colonic ACF probably due to dysregulation of cancer cell progression.
Keywords: 1, 2-dimethylhydrazine, Ranolazine, Aberrant crypt foci, Colon cancer